Mitogenic Signaling by the gep Oncogene Involves the Upregulation of S-Phase Kinase-Associated Protein 2

Abstract

The gep oncogene, defined by the activated mutant of the α-subunit of the G protein G₁₂ (Gα₁₂Q229L or Gα₁₂QL), potently stimulates the proliferation of many different cell types in addition to inducing neoplastic transformation of several fibroblast cell lines. While it has been demonstrated that Gα₁₂QL accelerates G1- to S-phase cell cycle progression, the precise mechanism through which Gα₁₂ communicates to cell cycle machinery is largely unknown. In the present study, we report that the activated—mutational as well as receptor-mediated—Gα₁₂ transmits its proliferative signals to cell cycle machinery by modulating the levels of the S-phase kinase-associated protein 2 (Skp2), an E3 ubiquitin ligase, involved in the regulation of the cyclin-dependent kinase inhibitor (CKI), p27^Kip1. Our results show that the expression of Gα₁₂QL leads to an increase in the levels of Skp2 with a correlatable decrease in p27^Kip1 levels and subsequent increase in the activities of specific CDKs. By demonstrating that the transient expression of Gα₁₂QL induces an increase in Skp2 levels with resultant downregulation of p27^Kip1 in both NIH3T3 and human astrocytoma 1321N1 cells, we establish here that the effect of Gα₁₂ on Skp2/p27^Kip1 is cell type independent. In addition, we demonstrate that LPA-stimulated proliferation and changes in Skp2 and p27^Kip1 levels in 1321N1 cells could be inhibited by the expression of a dominant-negative mutant of Gα₁₂, thereby pointing to the critical role of Gα₁₂ in LPA-mediated mitogenic signaling. Our findings also indicate that LPA as well as Gα₁₂-mediated upregulation of Skp2 requires a yet to be characterized mechanism involving JNK. Since Skp2 has been identified as an oncogene, and it is overexpressed in many cancers, our results presented here describe for the first time that Skp2 is a novel target in the cell cycle machinery through which Gα₁₂ and its cognate receptors transmit their oncogenic signals.

Keywords

oncogene G12 LPA Skp2 JNK

Introduction

GPCR-mediated signaling pathways have recently been identified to play a major role in cancer cell growth and progression.^1-5 Many GPCRs have been observed to be overexpressed in various cancer types, and they appear to contribute to tumor cell growth when activated by circulating or locally produced ligands. Confirming this view, a growing list of human cancers including ovarian, breast, prostate, and pancreatic carcinomas has been shown to exhibit aberrant expressions of GPCRs and the ligands that activate them.^4-10 In general, ligand-activated GPCRs stimulate diverse physiological responses by catalyzing the guanine nucleotide exchange in the α-subunit of different heterotrimeric G proteins.¹¹ Of the different α-subunits that have been analyzed thus far, the α-subunit of the G protein G₁₂ (Gα₁₂), referred to as the gep oncogene,¹² exhibits the most potent mitogenic and oncogenic activities.^11-13 Previous studies from our laboratory as well as others have identified different but complementary mechanisms through which Gα₁₂ promotes oncogenic proliferation.^11-24 Although these studies have indicated that Gα₁₂ promotes G1/S-phase progression^23,24—similar to many oncogenes—the mechanism by which Gα₁₂ communicates to cell cycle machinery is poorly understood. In light of the recent observations that Gα₁₂ and receptors that couple to Gα₁₂ are implicated in the genesis and/or progression of several cancers,^11-13 defining the mechanism(s) by which Gα₁₂ accelerates cell cycle progression may prove critically important to identify novel diagnostic, therapeutic, or prognostic targets.

Cell cycle analyses have indicated that mitogenic signaling pathways often converge onto mid to late G1 phase of cell cycle to accelerate cell progression into S phase.^25,26 In brief, cell cycle progression is regulated by a coordinated series of phosphorylation events, chiefly mediated by the cyclin-dependent kinase (CDK) family of serine/threonine kinases.^25-27 The activities of CDKs are regulated by the stimulatory cyclins and inhibitory cyclin-dependent kinase inhibitors (CKIs).^25-28 Once activated, cyclin-CDK complexes drive the cell cycle through its different phases via the phosphorylation of specific downstream targets such as retinoblastoma protein (pRb).^29,30 Our studies presented here are focused on identifying the mechanism by which Gα₁₂ communicates to this complex array of interrelated events to accelerate cell cycle progression. We demonstrate here that the expression of the constitutively activated mutant of Gα₁₂ stimulates the expression of cyclin D1 and cyclin A along with an increase in the activities of CDK2 and CDK4 in NIH3T3 cells. We show that the expression of Gα₁₂QL leads to a decrease in the levels of p27-kinase inhibitory protein-1 (p27^Kip1), a CKI primarily involved in the inhibition of CDK2 and CDK4.^26-28 We establish further that the decrease in p27^Kip1 accompanies the upregulation of S-phase kinase associated protein-2 (Skp2), an E3 ubiquitin ligase involved in downregulating p27^Kip1 levels.^31-34 The ability of transiently expressed Gα₁₂QL to recapitulate similar events in 1321N1 astrocytoma cells indicates that the effect of Gα₁₂ on the levels of Skp1 and p27^Kip1 is cell type independent. Our studies presented here also demonstrate that LPA, which has been identified as an oncogenic lipid growth factor in many cancers,^4,35-38 stimulates the proliferation of 1321N astrocytoma cells along with an increase in the levels of Skp2 via Gα₁₂. Finally, our studies point to JNK as a novel mediator in LPA/LPAR-Gα₁₂–mediated upregulation of Skp2. Taken together with the findings that Skp2 that has been defined as an oncogene^39-42 is overexpressed in many different cancers^43-48 similar to the upregulation of LPA-LPAR signaling in many cancers,^4,35-38 our data presented here unravel a potential role for Gα₁₂ and its cognate receptors in upregulating the levels of Skp2 in many cancers.

Results

Activated mutant of Gα₁₂ stimulates an increase in cyclin levels

To define Gα₁₂-mediated changes in cell cycle–associated proteins involved in G0-G1-S transition, we examined the profiles of different cyclins in NIH3T3 cells expressing Gα₁₂QL during G1-S progression. After verifying the expression of Gα₁₂QL (Fig. 1A), the levels of G1/S cyclins such as cyclin D1, cyclin E, and cyclin A were monitored by immunoblot analyses using lysates from NIH3T3 cells expressing Gα₁₂QL (Gα₁₂QL-NIH3T3) or the empty vector. Results from this analysis indicated that upon stimulation of cell proliferation by 5% serum, an increased expression of cyclin D1 can be observed in cells expressing Gα₁₂QL by 4 hours following serum stimulation, whereas such an increase can be seen in control cells only from 8 hours onwards (Fig. 1A). In contrast, an increase in cyclin A levels can be seen in Gα₁₂QL-NIH3T3 cells at all the time points compared to the vector control cells (Fig. 1B). In the case of cyclin E, Gα₁₂QL cells showed an increase—albeit small but consistent—in the basal levels compared to the vector controls. Thus, cells expressing Gα₁₂QL primarily showed an increase in the expression profiles of the G1/S-phase cyclins, cyclin D1 and cyclin A. An immunobot analysis of the G1/S phase–associated CDKs, namely, CDK2 and CDK4, showed no changes in their expression levels during these time points (Fig. 1C).

Figure 1.

Expression levels of G1/S-phase cyclins and CDKs in Gα₁₂QL-expressing cells. (A) Lysates (50 µg) from pcDNA3 vector control and Gα₁₂QL-transformed NIH3T3 cells (4 × 10⁵) were analyzed for the expression of Gα₁₂QL by immunoblot analysis using antibodies to Gα₁₂. The blot was reprobed with GAPDH to monitor equal loading of proteins. (B) Lysates (50 µg) prepared from vector control and Gα₁₂QL-NIH3T3 cells serum starved for 24 hours followed by stimulation with 5% CS for varying lengths of time were separated on a 10% SDS-PAGE and subjected to immunoblot analysis using antibodies specific to cyclin D1, cyclin A, or cyclin E. The blot was reprobed with antibodies to GAPDH to monitor equal loading of proteins. (C) An identical blot was probed for monitoring the levels of CDK4 and CDK2 using the respective antibodies. The blot was reprobed with antibodies to GAPDH to monitor equal loading of proteins. These analyses were repeated at least 3 times, and the results are from a typical analysis.

Gα₁₂ stimulates an increase in CDK activity

Since increased levels of cyclin D1 and cyclin A are often associated with a corresponding increase in CDK4 and CDK2 activities rather than their levels of expression,^25-27 we examined whether the increased levels of cyclins in Gα₁₂QL-expressing cells could be correlated with a corresponding increase in the activities of their catalytic partners CDK2 or CDK4. Lysates prepared from pcDNA3- and Gα₁₂QL-NIH3T3 cells that were stimulated with serum for different lengths of time were subjected to immune complex kinase assays using antibodies specific for CDK2 or CDK4.⁴⁹ CDK2 immune complex kinase assay was carried out using histone H1 as a substrate,⁴⁹ whereas CDK4 immune complex kinase assay was carried out using GST-Rb as the substrate.⁴⁹ As compared to the vector control, cells expressing Gα₁₂QL show a rapid and more potent increase in CDK2 as well as CDK4 activities (Fig. 2A and 2B), while their levels remain unaltered (Fig. 1B). Based on the findings that mitogenic pathways stimulate the rapid phosphorylation of Ser-795 of pRb through the cyclin D1–CDK4 and cyclin A–CDK2 complexes,^50,51 the phosphorylation status of Ser795 of pRb has been used as an index of the increased activities of CDK2/4.⁵² Therefore, we analyzed the phosphorylation of Ser795 of pRb in Gα₁₂QL-expressing cells to further assess and confirm the increase in the activities of CDK2/4. Results from such an immunoblot analysis indicated a rapid increase in the phosphorylated form of pRb in Gα₁₂QL-NIH3T3 cells upon serum stimulation compared to vector control cells (Fig. 2C).

Figure 2.

Gα₁₂QL stimulates the activation of CDKs. (A) CDK2 was immunoprecipitated from the lysates (100 µg) prepared from serum-deprived pcDNA3- and Gα₁₂QL-NIH3T3 that were stimulated with 5% calf serum for 0, 4, 8, and 12 hours using antibodies to CDK2. Immune complex kinase assay was carried out using purified histone H1 as a substrate. The phosphorylated histone H1 was separated by SDS-PAGE and visualized by autoradiography. (B) From the lysates (100 µg) as prepared above, CDK4 was immunoprecipitated with antibodies to CDK4, and immune complex kinase assay was carried out using purified recombinant GST-pRb as a substrate. The phosphorylated GST-pRb was separated by SDS-PAGE and visualized by autoradiography. (C) These lysates (50 µg) were separated on a 10% SDS-PAGE, and immunoblot analysis was carried out using antibodies specific to Ser795-phosphorylated pRb. The blot was stripped and reprobed with antibodies to pRb to monitor the expression levels. The blot was further probed with antibodies to GAPDH to monitor equal loading of proteins. The results presented are from a typical set of experiments that were repeated at least 3 times.

Gα₁₂ stimulates promitogenic changes in the levels of p27^Kip1 and Skp2

It has been well established that the activities of specific cyclin-CDK complexes are finely and dynamically regulated by distinct CDK inhibitors (CKIs).^25-28 Of the different CKIs, p27^Kip1 has been observed to play a major role in the regulation of CDK2/4 activities.^25-28 Therefore, we monitored the levels of p27^Kip1 in response to the expression of Gα₁₂QL. Vector control and Gα₁₂QL-NIH3T3 cells that were made quiescent by 24 hours of serum starvation were stimulated with 5% serum, and the lysates prepared from these cells at different time points were subjected to immunoblot analysis using antibodies to p27^Kip1. The results indicated that the cells expressing Gα₁₂QL showed an accelerated decrease in p27^Kip1 levels (from 8 hours) compared to vector control cells upon growth stimulation by serum (Fig. 3A). Since the levels of p27^Kip1 have been shown to be dynamically regulated via ubiquitin-mediated degradation of p27^Kip1 by the E3 ubiquitin ligase Skp2,^31-34 we investigated whether the observed decrease in p27^Kip1 levels in Gα₁₂QL-NIH3T3 cells is associated with an increase in the expression levels of Skp2. Results from such an analysis indicated an increase in Skp2 levels—during unstimulated as well as serum-stimulated conditions—in Gα₁₂QL cells compared to the vector control cells (Fig. 3B). To establish that the expression of Skp2 is not due to the clonal variation of a specific Gα₁₂QL-expressing clone of NIH3T3 cells, the expression levels of Skp2 and p27 were monitored in 3 different Gα₁₂QL-NIH3T3 clones. Results from such an experiment indicated that an increase in Skp2 levels along with a concomitant decrease in the levels of p27 could be observed in all the Gα₁₂QL-NIH3T3 clones (Fig. 3C), thus establishing that the observed decrease in Skp2 levels is not due to clonal variation. To further confirm that the increased levels of Skp2 are directly in response to Gα₁₂QL, the expression of Skp2 in response to transiently expressed Gα₁₂QL was monitored. Results from this analysis indicated that the transient expression of Gα₁₂QL stimulated the expression of Skp2 with a concomitant decrease in p27 levels (Fig. 3D), thereby confirming that the changes in Skp2-p27^Kip1 levels are directly in response to the expression of Gα₁₂QL.

Figure 3.

Gα₁₂ modulates the levels of p27^Kip1 and Skp2. (A) Lysates (50 µg) from pcDNA3- and Gα₁₂QL-NIH3T3 cells, serum starved for 24 hours and stimulated with 5% CS for the indicated lengths of time, were separated on a 10% SDS-PAGE and subjected to immunoblot analysis using antibodies specific to p27^Kip1. The blot was reprobed with GAPDH antibodies to monitor equal loading of proteins. (B) Lysates (50 µg) from pcDNA3-and Gα₁₂QL-NIH3T3 cells that were serum starved for 24 hours and stimulated with 5% CS for 0, 4, and 8 hours were subjected to immunoblot analysis using Skp2-specific antibodies. The blot was probed with antibodies to GAPDH to monitor equal loading of proteins. (C) Lysates (50 µg) were prepared from 2 independent pcDNA3- and 3 Gα₁₂QL-NIH3T3 cell clones that were serum starved for 24 hours and then stimulated with 5% CS for 0, 6, and 12 hours. Immunoblot analysis was carried out using Skp2-, p27^Kip1-, or GAPDH-specific antibodies. The experiment was repeated 3 times; results from a typical experiment are presented. (D) NIH3T3 cells that were infected with 600 MOI of Gα₁₂QL expressing adenovirus or empty pShuttle adenovirus were serum starved for 24 hours and then stimulated with 5% CS for the indicated time points (0, 6, and 12 hours). The blot prepared using the lysates (50 µg) from these cells were sequentially probed with antibodies specific to Skp2, p27^Kip1, and Gα₁₂.

Regulation of Skp2 by Gα₁₂ is cell type independent

Gα₁₂ has been shown to stimulate mitogenic signaling pathways in many different cell types including the astrocytoma cell line 1321N1.^12,22 Therefore, we investigated whether activated Gα₁₂ could induce changes in Skp2 levels in 1321N1 cells. Activated mutant of Gα₁₂ was transiently expressed in 1321N1 cells by infecting them with adenoviral vectors encoding Gα₁₂QL for 24 hours, and the expression levels of Skp2 were monitored using immunoblot analysis. Results indicated that the expression of activated mutant of Gα₁₂ stimulated the proliferation of 1321N1 cells, confirming previous studies (Fig. 4A). When lysates from these cells were subjected to immunoblot analyses to monitor the expressions of Skp2 and p27^Kip1, the results indicated that the cells expressing the activated mutant of Gα₁₂ showed an upregulation of Skp2 along with a concomitant decrease in p27^Kip1 (Fig. 4B). Together, these findings, for the first time, clearly establish the ability of Gα₁₂QL to increase the expression levels of Skp2 in 2 distinctly different cell types.

Figure 4.

Gα₁₂QL upregulates Skp2 in 1321N1 astrocytoma cells. (A) 1321N1 astrocytoma cells (5 × 10³ cells/well) were infected with 600 MOI of either Gα₁₂QL expressing adenovirus or empty pShuttle adenovirus. Proliferation of cells growing under low serum (2% FCS) was determined using an XTT-based cell proliferation kit as described in Materials and Methods. Fold increase was calculated by determining the increase in the absorbance of formazan dye at 492 nm over a period of 24 hours. The expression of Gα₁₂QL was monitored by immunoblot analysis of lysates prepared from an identical set of these cells using Gα₁₂-specific antibodies (lower panel). (B) 1321N1 astrocytoma cells infected with 600 MOI of Gα₁₂QL expressing adenovirus or the empty pShuttle adenovirus were stimulated with 5% FBS for 0, 6, and 12 hours. Lysates (50 µg) from these cells were analyzed for the expression of Skp2, p27^Kip1, and Gα₁₂ by immunoblot analysis using respective antibodies. The blot was reprobed with antibodies to GAPDH to ascertain equal loading of proteins.

Gα₁₂ mediates LPA-stimulated cell proliferation and Skp2 upregulation in 1321N astrocytoma cells

The findings that the mutationally activated Gα₁₂ stimulated the upregulation of Skp2 raised an interesting question whether receptor activation of endogenous Gα₁₂ would lead to similar changes in the levels of Skp2 and p27^Kip1. This was analyzed with the use of LPA, an oncogenic lipid growth factor, which is known to stimulate cell proliferation via Gα₁₂. After confirming that LPA (60 µM) stimulated the proliferation of 1321N1 cells (Fig. 5A), the expression profiles of Skp2 and p27^Kip1 in LPA-stimulated cells were monitored by immunoblot analysis. Results indicated that LPA stimulated a strong increase in the levels of Skp2 along with a drastic decrease in p27^Kip1 levels by 24 hours compared to the unstimulated controls (Fig. 5B). To test whether the effects of LPA on Skp2 and p27^Kip1 involve Gα₁₂, we analyzed the effect of expressing the dominant-negative mutant of Gα₁₂ on LPA-stimulated changes in Skp2/ p27^Kip1 levels. Based on the findings that the C-termini of G protein α-subunits are critical for binding to their cognate receptors,⁵³ an adenoviral vector that encodes the C-terminal 11 amino acids of Gα₁₂ (CT-12) has been successfully used in 1321N1 astrocytoma cells to inhibit Gα₁₂-specific responses.⁵⁴ Using this adenoviral construct, we analyzed the role of Gα₁₂ in LPA-mediated cell proliferation and associated changes in Skp2-p27^Kip1 levels. Results from these analyses indicated that the proliferation of 1321N1 cells stimulated by LPA could be effectively inhibited by the expression of the dominant-negative mutant of Gα₁₂ (Fig. 5C). Similarly, the expression of CT-12 attenuated the LPA-stimulated upregulation of Skp2 along with the associated increase in p27^Kip1 levels (Fig. 5D). Taken together, these results clearly establish that the LPA-stimulated increase in Skp2, associated downregulation of p27^Kip1, and the resultant cell proliferation in 1321N1 cells require Gα₁₂, the inhibition of which attenuates all of these events.

Figure 5.

LPA upregulates Skp2 via Gα₁₂. (A) Serum-deprived 1321N1 astrocytoma cells (5 × 10³ cells/well) were stimulated with 60 µM of LPA for 24 hours along with the unstimulated control group. The increase in cell numbers at 24, 48, and 72 hours was monitored using crystal violet–based dye binding assay as described in Materials and Methods. A fold increase at 24 hours was calculated to the absorbance at 0 hours. (B) Serum-deprived 1321N1 astrocytoma cells were stimulated with 60 µM of LPA for varying lengths of time (0, 8, 16, and 24 hours) along with unstimulated controls. Lysates (50 µg) from these cells were analyzed for the expression levels of Skp2 and p27^Kip1 by immunoblot analysis using respective antibodies. The blot was reprobed with GAPDH antibodies to monitor equal protein loading. (C) Quiescent 1321N1 astrocytoma cells (5 × 10³ cells/well) infected with 150 MOI of CT-12 encoding adenovirus or empty pShuttle adenovirus (24 hours) were stimulated with LPA (60 µM) for 24 hours. Cell proliferation was measured using the XTT-based cell proliferation assay as described in Materials and Methods. Fold increase in cell proliferation was calculated by monitoring the increase in the absorbance of the formazan dye at 490 nm over a period of 24 hours. The expression of CT-12 was monitored by immunoblot analysis of lysates prepared from identical set-up experimental samples, using the Gα₁₂ antibody that recognizes the CT-12 (lower panel). (D) Lysates (50 µg) from these cells were subjected to immunoblot analysis using Skp2, p27^Kip1, or GAPDH. The results are from a representative set of experiments (n = 3).

Gα₁₂ regulation of Skp2 is mediated by JNK

Being a critical player in G0-G1-S–phase transition, Skp2 is regulated by multiple signaling pathways involving ERKs,⁵⁵ AKT,⁵⁶ and FAK.⁵⁷ However, it is significant to note here that Gα₁₂-mediated mitogenic signaling critically involves the potent activation of JNKs.^12,14-16 Therefore, we examined whether LPA-mediated increase in Skp2 levels involves JNK, the dominant signaling pathway utilized by Gα₁₂. As shown in Figure 6A, inhibition of JNKs using SB600125 potently attenuated the increase in Skp2 levels stimulated by LPA in 1321N1 cells. Consistent with this observation, treating NIH3T3 cells expressing Gα₁₂QL with SB600125 resulted in a similar inhibition in the upregulation of Skp2 compared to vehicle-treated Gα₁₂QL-NIH3T3 cells (Fig. 6B). Previous studies have shown that Gα₁₂-mediated activation of JNK involves the small GTPase CDC42.¹⁵ Consistent with this observation, inhibition of CDC42 by expressing CDC42 N17, a dominant-negative mutant of CDC42, attenuated Gα₁₂QL-mediated upregulation of Skp2 levels in 1321N1 cells (Fig. 6C). These results pointing out a role for JNK in LPA- and Gα₁₂-mediated upregulation of Skp2 are quite novel and hitherto unreported.

Figure 6.

LPA-Gα₁₂–mediated upregulation of Skp2 involves JNK. (A) 1321N1 astrocytoma cells (0.5 × 10⁶ cells/60-mm plate) were treated with SP600125 (50 µM) or DMSO 2 hours prior to stimulation with 60 µM for 24 hours. Lysates (50 µg) from these cells were subjected to immunoblot analysis using antibodies to Skp2. The blot was stripped and reprobed with GAPDH antibodies to monitor equal loading of proteins. (B) Lysates (50 µg) from pcDNA3- and Gα₁₂QL-NIH3T3 cells that were treated with SP600125 (50 µM) or DMSO 2 hours prior to stimulation with 5% CS for 0, 4, 8, 12, and 16 hours and analyzed for Skp2 levels by immunoblot analysis using Skp2 antibodies. The blot was reprobed with GAPDH antibodies to monitor equal loading of proteins. Results are from a typical experiment (n = 3). (C) 1321N1 astrocytoma cells (5 × 10³ cells/well) were infected with 600 MOI of Gα₁₂QL-encoding adenoviral vector singly or in combination with CDC42 N17-encoding adenoviral vectors along with appropriate control vectors. After 24 hours, the cells were stimulated with LPA (60 µM) for 24 hours. Lysates (50 µg) from these cells were subjected to immunoblot analysis using antibodies to Skp2, Gα₁₂, CDC42, or GAPDH. The results are from a representative set of experiments (n = 3).

Discussion

Gα₁₂, the α-subunit of G₁₂ that constitutes the gep oncogene, has been shown to be the most potent α-subunit in promoting cell proliferation and neoplastic transformation.^11-13,58,59 While studies describing the diversity of signals generated from Gα₁₂ in inducing proliferation have been extensively documented, the mechanism by which mitogenic signaling cues from Gα₁₂ are integrated in to the G1 to S phase of the cell cycle is relatively unknown. The results presented here identify for the first time a multipartite, but interrelated, mechanism(s) through which Gα₁₂ communicates to cell cycle machinery. An overview of these pathways establishes a paradigm in which the multiple targets involved in Gα₁₂-mediated mitogenic signaling converge towards the stimulation and potentiation of CDK activities. The first target of Gα₁₂ signaling appears to be the upregulation of the levels of different G0/G1/S-phase stimulatory cyclins. The second set of targets involves the stimulation of the respective CDKs via p27^Kip1 and Skp2. As can be seen in Figure 1, the expression of Gα₁₂ promotes an increase in the levels of cyclin D1, A, and E. Although the mechanism by which Gα₁₂ upregulates these levels was not investigated in the present study, the ability of Gα₁₂ to stimulate Akt signaling in these cells as previously demonstrated by us²¹ and the subsequent Akt-mTOR–mediated stimulation of cellular translational apparatus appears to play a major role in this process (Ha and Dhanasekaran, unpublished data). Activation of the cyclin D1–CDK4 complex has been shown to play a critical role in inducing G1- to S-phase progression.^26-30 Similarly, cyclin A–CDK2 has been established as a key promoter of the S phase of the cell cycle.^25,26 By stimulating an increase in the levels of the respective cyclins and their associated CDKs, Gα₁₂ signaling appears to target 2 complementary critical components of cell cycle machinery to ensure accelerated G1/S-phase progression. This is further substantiated by the observed increase in the phosphorylation of Ser795 of pRb in Gα₁₂QL-expressing cells (Fig. 2D) since an increase in the activities of both cyclin D–CDK4 and cyclin A–CDK2 activity has been shown to contribute to the efficient phosphorylation of pRb, thereby relieving its inhibitory effect on S-phase entry. Thus, in addition to upregulating the levels of cyclins, Gα₁₂ is also involved in stimulating the activities of the respective CDKs. The answer to the question as to how Gα₁₂ stimulates the activities of CDK2/4 appears to lie, at least in part, within the ability of Gα₁₂ to modulate the levels of p27^Kip1 through Skp2.

It should be noted here that during G1/S-phase progression, p27^Kip1 plays a dominant role in negatively regulating CDK2/4.^26-28 In turn, p27^Kip1 levels are dynamically regulated by the degradation of p27^Kip1 by ubiquitin proteosome machinery involving Skp2.^31-34 Our results presented here show that Gα₁₂QL stimulates the upregulation of Skp2 along with a concomitant decrease in p27^Kip1 levels (Fig. 3A and 3B). Thus, the increase in CDK activities seen in Gα₁₂QL cells possibly results from the decreased levels of p27^Kip1 brought out by the upregulated Skp2. Modulation of Skp2 levels appears to be one of the major mechanisms through which mitogens regulate the activities of CDKs in stimulating cell cycle progression.^26-34 In this context, our observation that Gα₁₂ signaling stimulates an increase in Skp2 levels along with the downregulation of p27^Kip1 in 2 different cell types (Figs. 3 and 4) in which Gα₁₂ promotes proliferation strongly identifies Skp2 as a major signaling target—in addition to cyclins—by which Gα₁₂ promotes G1- to S-phase progression. It should be noted here that Skp2 is also involved in maintaining the optimal levels of cyclin E during G1/S transition.³⁴ Thus, it is likely that the observed decrease in cyclin E levels upon growth stimulation (Fig. 1B) is in response to the elevated Skp2 levels in Gα₁₂QL cells (Fig. 3). Given the primary role of Skp2 in regulating CKIs and other key players in cell cycle progression, the results presented here that Gα₁₂ upregulates Skp2 are highly significant. In addition, considering the potent mitogenic activity of Gα₁₂, our findings unravel Skp2 as the novel target in the cell cycle machinery through which Gα₁₂ accelerates G1- to S-phase cell cycle progression and subsequent cell proliferation.

Our studies presented here also identify 2 newer correlates on LPA-mediated mitogenic signaling: 1) LPA stimulates proliferation along with promitogenic changes in Skp2/p27^Kip1 levels via Gα₁₂, and 2) LPA-Gα₁₂–mediated upregulation of Skp2 involves JNK. While the increase in LPA levels and LPA-LPAR–mediated signaling have been implicated in the growth and progression of many tumors, the mechanisms through which it promotes such oncogenic activities are largely unknown. Our results demonstrating that LPA stimulates proliferation of 1321N1 astrocytoma cells along with the upregulation of Skp2 with the resultant downregulation of p27^Kip1 that can promote cell cycle progression (Fig. 5A and 5B), both of which can be inhibited by the dominant-negative mutant of Gα₁₂ (Fig. 5C and 5D), constitute the first demonstration of a cell cycle–based mechanism through which the oncogenic growth factor LPA and Gα₁₂, the gep oncogene, stimulate the mitogenic pathway. Another interesting aspect of LPA-Gα₁₂–mediated upregulation of Skp2 relates to our finding that JNK is involved in this process. The expression of Skp2 is known to be regulated by different kinases including ERK, AKT, and FAK.^49,55-57 Until now, JNK is not known as one of the kinases involved in the regulation of Skp2. In this context, our results indicating a role for JNK in LPA- and Gα₁₂-mediated upregulation of Skp2 (Fig. 6) are quite important as they identified a so far unknown JNK-dependent mechanism underlying the regulation of Skp2. Although the mechanism(s) by which JNK mediates an increase in Skp2 levels is not clear at present, further studies should clarify its precise role in Gα₁₂-mediated upregulation of Skp2.

Taken together, our results support a model in which Gα₁₂-mediated increase in the levels of stimulatory cyclins as well as the decrease in the levels of p27^Kip1 through the upregulation of Skp2 cumulatively contribute to the overall increase in the activities of cyclin-CDK complexes, thereby accelerating G1/S progression. A simplistic working model integrating LPA-LPAR-Gα₁₂ signaling to cell cycle machinery is presented in Figure 7. In light of the observations that 1) Skp2 levels are increased in glioblastomas⁴⁶ and astrocytic gliomas,⁴⁷ 2) LPA is locally produced in many different cancers including glioblastomas,^4,38 3) LPA-LPAR signaling can promote cell growth and cancer progression through the facilitation of autocrine and paracrine signaling loops,^4,7,35-39 and 4) Gα₁₂ transmits signals from LPA-LPAR to intracellular effector molecules through JNK,^11,58 our identification of Skp2 as the target protein regulated by Gα₁₂ is highly significant. Although finer details of this working model remain to be filled in, with the identification of Skp2 as a major protein being regulated by LPA-LPAR-Gα₁₂ signaling, further studies should define the role of this signaling nexus as well as other critical players involved in this signaling pathway in the genesis and progression of various cancers.

Figure 7.

Schematic model for Gα₁₂-mediated cell cycle progression. Receptor or mutationally activated Gα₁₂ accelerates G1-S progression by upregulating the levels of specific cyclins and Skp2, both of which contribute to the increased activities of CDKs. While cyclins stimulate their respective CDKs, CDK activities could be further potentiated by Skp2, which downregulates the levels of p27^Kip1, an inhibitory CKI, via the ubiquitin-proteosome degradation system. Gα₁₂-mediated upregulation of Skp2 involves a novel signaling node involving CDC42 and JNK.

Materials and Methods

Cell lines

Parental NIH3T3, 1321N1 astrocytoma cells as well as previously described pcDNA3-NIH3T3 and Gα₁₂Q229L-NIH3T3 cell lines were maintained as described earlier²¹ in Dulbecco’s modified Eagle’s medium (DMEM) (Cellgro, Mediatech Inc., Manassas, VA) containing 50 U/mL penicillin, 50 µg/mL streptomycin, and 5% calf serum (NIH3T3 cells) or 5% fetal bovine serum (1321N1 cells) at 37°C in a 5% CO₂ incubator. The sera were obtained from Life Technologies Inc. (Gaithersburg, MD).

Adenoviral constructs

Construction of adenoviral vector–expressing Gα₁₂QL was carried out using the cDNA insert encoding Gα₁₂QL (1,800 bp) excised from the pcDNA3-Gα₁₂QL vector¹⁴ using the restriction nucleases KpnI and XbaI. The cohesive ends were blunted and cloned in the EcoRV site of the pShuttle-IRES-GFP2 vector (Stratagene, La Jolla, CA). The resultant plasmid was linearized using PmeI before it was transformed into Escherichia coli BJ5183-AD-1 cells (pretransformed with pAdEasy-1 plasmid) in which the homologous recombination event with the pAdEasy-1 plasmid containing adenoviral backbone could take place. The recombinant clones were selected by analysis of the PacI-digested DNA from these clones. The positive recombinant DNA was amplified by transforming it on a suitable E. coli strain. The recombinant DNA was cut with PacI and then purified before transfection onto AD293 cells for the virus production. Isolation of the virus was carried out following the standard freeze-thaw procedure. If needed, further amplification of the virus was carried out using AD293 cells. These recombinant adenoviruses were titrated by plaque assay before target cells were infected. Adenoviral vectors expressing the dominant-negative mutant of CDC42 were constructed following identical procedures, using the Bam I–Xho1 insert of CDC42 N17.⁶¹ Recombinant adenoviral vector expressing the dominant-negative mutant of Gα₁₂, CT-12,⁵⁴ was kindly provided by Dr. Yoh Takuwa (Kanazawa University Graduate School of Medicine, Kanazawa, Japan). This virus was amplified by infecting AD293 cells. These recombinant adenoviruses were titrated by plaque assay before using them for infecting the target cells.

Determining the optimal multiplicity of infection (MOI)

Based on the titer obtained from the plaque assay, the volume of virus that corresponds to the particular MOI to be infected was determined. An equal number of NIH3T3 and 1321N1 astrocytoma cells (1 × 10⁶ cells/plate) were plated on 100-mm culture plates and infected with different MOIs (0, 25, 100, 300, and 600) of the adenovirus. Media containing serum were removed from the plates and washed with PBS and then replaced with 2 mL of serum-free medium containing the adenovirus. The plates were kept in the rocker inside the incubator for 2 hours for the cells to get infected. Following this, the plates were replaced with growth medium containing serum and incubated for 24 hours. Lysates were prepared from these cells and analyzed for the expression of proteins encoded by the adenovirus. Based on the expression profile, the optimum MOI to be used for the experiment was determined. The optimal MOI was deduced as the one at which the transgene showed the highest expression with little or no cytotoxic effects. Based on these results, an MOI of 600 was used for both NIH3T3 cells and 1321N1 astrocytoma cells. In experiments in which low serum growth conditions were used, the MOI was reduced to 150.

Cell proliferation assay

The growth profile of 1321N cells in response to LPA was monitored using an assay based on crystal violet staining of live cells following previously published procedures.⁶⁰ An equal number of 1321N1 cells (5 × 10³) grown on 12-well plates were serum starved for 24 hours, after which they were stimulated with 60 µM of LPA for 24, 48, and 72 hours, respectively. At specific time points, cells were fixed using 10% formalin (Fisher Scientific, Pittsburgh, PA) dissolved in PBS for 10 minutes, following which the fixed samples were stained with 0.1% crystal violet (Sigma-Aldrich, St. Louis, MO) for 6 hours. The samples were then washed extensively to remove excess dye and dried overnight. The cell-associated dye was then extracted by incubation with 1 mL acetic acid (Fisher Scientific) for 60 seconds. The optical density of each sample was quantified at 590 nm. Proliferation of 1321N1 astrocytoma cells transiently infected with adenovirus encoding CT-12 or empty pShuttle adenovirus was monitored using the XTT [2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino) carbonyl]-2H-tetrazolium hydroxide]–based cell proliferation assay kit (Roche Diagnostics, Indianapolis, IN). An equal number of cells (5 × 10³ cells/well) grown in 96-well plates were serum starved for 24 hours. These cells were infected with an MOI of 150 of either pShuttle or CT-12 adenovirus in freshly replaced serum starvation medium supplemented with 0.2% fetal bovine serum followed by stimulation with LPA (60 µM) for 24 hours. The absorbance of formazan dye at 490 nm was monitored as an index of actively growing cells using a microplate reader.

Immunoblot analysis

Immunoblot analyses were carried out following the previously published procedures.²¹ Antibodies to Gα₁₂ (sc-409), cyclin A (sc-596), cyclin D1 (sc-8396), cyclin E (sc-481), CDK4 (sc-601), CDK2 (sc-163), p27^Kip1 (sc-528), Skp2 (sc-7164), JNK1 (sc-474), and JNK2 (scv-827) were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). Antibodies to phospho-pRb (Ser795; #9301), control Rb (#9302), and phospho-JNK (#9251) were purchased from Cell Signaling Technology Inc. (Danvers, MA). Antibodies to GAPDH (#4300) were purchased from Ambion Inc. (Austin, TX). Peroxidase-conjugated anti-mouse IgG and anti-rabbit IgG were purchased from Amersham Biosciences UK Ltd. (Little Chalfont, Buckinghamshire, UK) and Promega (Madison, WI), respectively.

Immune complex kinase assays

Immune complex kinase assays to monitor the kinase activities of CDK2 and CDK4 were carried out using previously published procedures with appropriate modifications.⁴⁵ Cells were lysed with kinase lysis buffer (200 µL) containing 20 mM HEPES (pH 7.4), 50 mM β-glycerophosphate, 0.5% Triton X-100, 2 mM MgCl₂, 1 mM EGTA, 1 mM dithiothreitol, 2 µg/mL leupeptin, 4 µg/mL aprotinin, 100 µm PMSF, and 1 mM benzamidine. CDK2 or CDK4 in the lysates was immunoprecipitated by incubating 200 µg of protein lysate with the polyclonal antibodies specific to CDK2 (sc-163; 2 µg) or CDK4 (sc-601; 2 µg), respectively, for 1 hour. This was followed by an additional incubation with 20 µL of protein A–Sepharose (Amersham Biosciences Corp., Piscataway, NJ) for 1 hour. The immune complex–bound protein A–Sepharose beads were washed 3 times with lysis buffer. CDK2 immune complex assay was carried out with protein A–Sepharose–bound CDK2 using 5 µg of histone H1 (Roche Diagnostics). CDK4 immune complex assay was carried out with protein A–Sepharose–bound CDK2 using 5 µg of GST-Rb fusion protein (a generous gift from Dr. Fang Liu, Rutgers University, New Brunswick, NJ). The kinase reactions were carried out by resuspending the protein A–Sepharose beads with bound immune complexes containing CDK2 or CDK4 along with appropriate substrates in 40 µL of kinase reaction buffer containing 20 µM [γ-³²P] ATP (5,000 cpm/pmol) and incubating at 30°C for 30 minutes. The reaction was stopped by the addition of Laemmli’s sample buffer followed by boiling the sample for 3 minutes. The proteins were resolved by 12% SDS-PAGE, and the dried gels were analyzed by autoradiography.

Footnotes

Acknowledgements

The generous gift of CT-12 adenoviral constructs expressing the dominant-negative mutant of Gα₁₂ by Dr. Y. Takuwa (Kanazawa University Graduate School of Medicine, Kanazawa, Japan) and the critical reading of the paper by Dr. Lakshmi Varadarajalu are gratefully acknowledged.

The author(s) declared no potential conflicts of interest with respect to the authorship and/or publication of this article.

This work was supported by grants from the National Institutes of Health [CA123233] and World Class University project funded by Ministry of Education, Science and Technology Development, South Korea [No. R32-2008-000-10098-0].

References

Huang

Peng

. Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression. Int J Oncol. 2005;27:1329-39.

Dorsam

Gutkind

. G-protein-coupled receptors and cancer. Nat Rev Cancer. 2007;7:79-94.

Bhola

Grandis

. Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Front Biosci. 2008;13:1857-65.

Liu

Murph

Panupinthu

Mills

. ATX-LPA receptor axis in inflammation and cancer. Cell Cycle. 2009;8:3695-701.

Arora

Ricks

Trejo

. Protease-activated receptor signalling, endocytic sorting and dysregulation in cancer. J Cell Sci. 2007;120:921-8.

Mazzuco

Chabre

Feige

Thomas

. Aberrant GPCR expression is a sufficient genetic event to trigger adrenocortical tumorigenesis. Mol Cell Endocrinol. 2007;265-266:23-8.

Mills

Eder

Fang

. Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer. Cancer Treat Res. 2002;107:259-83.

Aly

Shulkes

Baldwin

. Gastrins, cholecystokinins and gastrointestinal cancer. Biochim Biophys Acta. 2004;1704:1-10.

Yowell

Daaka

. G protein-coupled receptors provide survival signals in prostate cancer. Clin Prostate Cancer. 2002;1:177-81.

10.

Hull

Hawcroft

. Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer? Mol Cancer Ther. 2004;3:1031-9.

11.

Juneja

Casey

. Role of G12 proteins in oncogenesis and metastasis. Br J Pharmacol. 2009;158:32-40.

12.

Radhika

Dhanasekaran

. Transforming G proteins. Oncogene. 2001;20:1607-14.

13.

Grzelinski

Pinkenburg

Büch

. Critical role of Gα₁₂ and Gα₁₃ for human small cell lung cancer cell proliferation in vitro and tumor growth in vivo. Clin Cancer Res. 2010;16:1402-15.

14.

Prasad

Dermott

Heasley

Johnson

Dhanasekaran

. Activation of Jun kinase/stress-activated protein kinase by GTPase-deficient mutants of Gα₁₂ and Gα₁₃ . J Biol Chem. 1995;270:18655-9.

15.

Voyno-Yasenetskaya

Faure

Ahn

Bourne

. Gα₁₂ and Gα₁₃ regulate extracellular signal-regulated kinase and c-Jun kinase pathways by different mechanisms in COS-7 cells. J Biol Chem. 1996;271:21081-7.

16.

Collins

Minden

Karin

Brown

. Gα₁₂ stimulates c-Jun NH₂-terminal kinase through the small G proteins Ras and Rac. J Biol Chem. 1996;271:17349-53.

17.

Jiang

Wan

Kozasa

Hattori

Huang

. The G protein Gα₁₂ stimulates Bruton’s tyrosine kinase and a rasGAP through a conserved PH/BM domain. Nature. 1998;395:808-13.

18.

Dermott

Reddy

Onesime

Reddy

Dhanasekaran

. Oncogenic mutant of Gα₁₂ stimulates cell proliferation through cycloxygenase-2 signaling pathway. Oncogene. 1999;18:7185-9.

19.

Dermott

Lee

Dhanasekaran

. Differential regulation of Jun N-terminal kinase and p38MAP kinase by Gα₁₂ . Oncogene. 2004;23:226-32.

20.

Kumar

Shore

Dhanasekaran

. Neoplastic transformation by the gep oncogene, Gα₁₂, involves signaling by STAT3. Oncogene. 2006;25:899-906.

21.

Kumar

Radhakrishnan

Dhanasekaran

. Transactivation of platelet-derived growth factor receptor α by the GTPase-deficient activated mutant of Gα₁₂ . Mol Cell Biol. 2006;26:50-62.

22.

Aragay

Collins

Post

. G12 requirement for thrombin-stimulated gene expression and DNA synthesis in 1321N1 astrocytoma cells. J Biol Chem. 1995;270:20073-7.

23.

Kumar

Radhakrishnan

Dhanasekaran

. Proteome analysis of NIH3T3 cells transformed by activated Gα₁₂: regulation of leukemia-associated protein SET. J Proteome Res. 2004;3:1177-83.

24.

Mitsui

Takuwa

Kurokawa

Exton

Takuwa

. Dependence of activated Gα₁₂-induced G1 to S phase cell cycle progression on both Ras/mitogen-activated protein kinase and Ras/Rac1/Jun N-terminal kinase cascades in NIH3T3 fibroblasts. J Biol Chem. 1997;272:4904-10.

25.

Sherr

. G1 phase progression: cycling on cue. Cell. 1994;79:551-5.

26.

Grana

Reddy

. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene. 1995;11:211-9.

27.

Malumbres

Barbacid

. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9:153-66.

28.

Besson

Dowdy

Roberts

. CDK inhibitors: cell cycle regulators and beyond. Dev Cell. 2008;14:159-69.

29.

Grana

Garriga

Mayol

. Role of the retinoblastoma protein family, pRB, p107 and p130 in the negative control of cell growth. Oncogene. 1998;17:3365-83.

30.

Adams

. Regulation of the retinoblastoma tumor suppressor protein by cyclin/cdks. Biochim Biophys Acta. 2001;1471:M123-33.

31.

Tsvetkov

Yeh

Lee

Sun

Zhang

. p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol. 1999;9:661-4.

32.

Carrano

Eytan

Hershko

Pagano

. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol. 1999;1:193-9.

33.

Pegano

. Control of DNA synthesis and mitosis by the Skp2-p27-Cdk1/2 axis. Mol Cell. 2004;14:414-6.

34.

Nakayama

K-I

Hatakeyama

Nakayama

. Regulation of the cell cycle at the G1-S transition by proteolysis of cyclin E and p27^Kip1 . Bioche Biophys Res Commun. 2001;282:853-60.

35.

Panupinthu

Lee

Mills

. Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression. Br J Cancer. 2010;102:941-6.

36.

Daaka

. Mitogenic action of LPA in prostate. Biochim Biophys Acta. 2002;1582:265-9.

37.

Yamada

Sato

Komachi

. Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1. J Biol Chem. 2004;279:6595-605.

38.

Kishi

Okudaira

Tanaka

. Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidy-lcholine to lysophosphatidic acid. J Biol Chem. 2006;281:17492-500.

39.

Latres

Chiarle

Schulman

. Role of the F-box protein Skp2 in lymphomagenesis. Proc Natl Acad Sci U S A. 2001;98:2515-20.

40.

Gstaiger

Jordan

Lim

. Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci U S A. 2001;98:5043-8.

41.

Hershko

. Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer. Cancer. 2008;112:1415-24.

42.

Signoretti

Di Marcotullio

Richardson

. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest. 2002;110:633-41.

43.

Yang

Ayala

De Marzo

. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res. 2002;8:3419-26.

44.

Einama

Kagata

Tsuda

. High-level Skp2 expression in pancreatic ductal adenocarcinoma: correlation with the extent of lymph node metastasis, higher histological grade, and poorer patient outcome. Pancreas. 2006;32:376-81.

45.

Shigemasa

O’Brien

Ohama

. Skp2 overexpression is a prognostic factor in patients with ovarian adenocarcinoma. Clin Cancer Res. 2003;9:1756-63.

46.

Saigusa

Hashimoto

Tsuda

. Overexpressed Skp2 within 5p amplification detected by array-based comparative genomic hybridization is associated with poor prognosis of glioblastomas. Cancer Sci. 2005;96:676-83.

47.

Schiffer

Cavalla

Fiano

Ghimenti

Piva

. Inverse relationship between p27/Kip.1 and the F-box protein Skp2 in human astrocytic gliomas by immunohistochemistry and Western blot. Neurosci Lett. 2002;328:125-8.

48.

Kudo

Kitajima

Sato

Miyauchi

Ogawa

Takata

. High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas. Cancer Res. 2001;61:7044-7.

49.

Modiano

Domenico

Szepesi

Lucas

Gelfand

. Differential requirements for interleukin-2 distinguish the expression and activity of the cyclin-dependent kinases Cdk4 and Cdk2 in human T cells. J Biol Chem. 1994;269:32972-8.

50.

Connell-Crowley

Harper

Goodrich

. Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol Biol Cell. 1997;8:287-301.

51.

Zarkowska

Mittnacht

. Differential phosphorylation of the retinoblastoma protein by G1/S cyclin-dependent kinases. J Biol Chem. 1997;272:12738-46.

52.

Gao

Flynn

Zhang

. G cell cycle progression and the expression of G₁ cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol. 2004;287:C281-91.

53.

Gilchrist

Vanhauwe

Thomas

Voyno-Yasenetskaya

Hamm

. Gα minigenes expressing C-terminal peptides serve as specific inhibitors of thrombin mediated endothelial activation. J Biol Chem. 2001;276:25672-9.

54.

Sugimoto

Takuwa

Okamoto

Sakurada

Takuwa

. Inhibitory and stimulatory regulation of Rac and cell motility by the G12/13-Rho and Gi pathways integrated downstream of a single G protein-coupled sphingosine-1-phosphate receptor isoform. Mol Cell Biol. 2003;23:1534-45.

55.

Villanueva

Yung

Walker

Assoian

. ERK activity and G1 phase progression: identifying dispensable versus essential activities and primary versus secondary targets. Mol Biol Cell. 2007;18:1457-63.

56.

Lin

Wang

Chen

. Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. Nat Cell Biol. 2009;11:420-32.

57.

Bryant

Zheng

Pumiglia

. Focal adhesion kinase controls cellular levels of p27/^Kip1 and p21/Cip1 through Skp2-dependent and -independent mechanisms. Mol Cell Biol. 2006;26:4201-13.

58.

Radhika

Jayaraman

Tsim

Dhanasekaran

. Mitogenic signaling by lysophosphatidic acid (LPA) involves Gα₁₂ . Oncogene. 2005;24:4597-603.

59.

Goldsmith

Dhanasekaran

. G protein regulation of MAPK networks. Oncogene. 2007;26:3122-42.

60.

Orsulic

Soslow

Vitale-Cross

Gutkind

Varmus

. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell. 2002;1:53-62.

61.

Wadsworth

Gebauer

van Rossum

GDV

Dhanasekaran

. Ras-dependent signaling by the GTPase-deficient mutant of Gα₁₂ . J Biol Chem. 1997;272:28829-32.

Mitogenic Signaling by the gep Oncogene Involves the Upregulation of S-Phase Kinase-Associated Protein 2

Abstract

Keywords

Introduction

Results

Activated mutant of Gα12 stimulates an increase in cyclin levels

Gα12 stimulates an increase in CDK activity

Gα12 stimulates promitogenic changes in the levels of p27Kip1 and Skp2

Regulation of Skp2 by Gα12 is cell type independent

Gα12 mediates LPA-stimulated cell proliferation and Skp2 upregulation in 1321N astrocytoma cells

Gα12 regulation of Skp2 is mediated by JNK

Discussion

Materials and Methods

Cell lines

Adenoviral constructs

Determining the optimal multiplicity of infection (MOI)

Cell proliferation assay

Immunoblot analysis

Immune complex kinase assays

Footnotes

Acknowledgements

References

Activated mutant of Gα₁₂ stimulates an increase in cyclin levels

Gα₁₂ stimulates an increase in CDK activity

Gα₁₂ stimulates promitogenic changes in the levels of p27^Kip1 and Skp2

Regulation of Skp2 by Gα₁₂ is cell type independent

Gα₁₂ mediates LPA-stimulated cell proliferation and Skp2 upregulation in 1321N astrocytoma cells

Gα₁₂ regulation of Skp2 is mediated by JNK